This happended after Q4 CC, and those analysts had to change their numbers because they will look like fools after relistor inidcation expansion approval.
Also, I talked to the company's representive last week, just knowing the idea/approach to start with advanced patient indication then chronic indication was FDA's recommendation to PGNX. Now, relistor has been on market for 4 years now, and there had been no safety issue directly related relistor usage, and one year chronic pain safety trial result was very good in both efficancy and safety. We have no reason to not see this label expension approved on time.
Just a little bit more than a month to go...
Good luck to shorts because they really needed this time around